非腫瘍遺伝子の依存症の同期性オリゴメタスタティック非小細胞肺がんにおける現在の論争と課題:レビュー
Mandy Jongbloed1, Martina Bortolot2, Jonas Willmann3,4
1Department of Pulmonary Diseases, GROW - Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands.
JAMA oncology
|September 4, 2025
まとめ
局所急激療法 (LRT) は,維持免疫療法を受けている同期性小胞性非小胞性肺がん (NSCLC) の患者の生存率を向上させなかった. 真のオリゴメタスタティック状態の存在は不明である.
科学分野:
- 腫瘍学
- 医療用イメージング
- ゲノミクス
背景:
- 画像と治療の進歩は,同期性オリゴメタスタシス疾患 (sOMD) の治療目的の潜在的な利点を示唆しています.
- NRG- LU002試験では,小細胞肺がん (NSCLC) の維持性全身療法に局所性急激療法 (LRT) を加えることを調査した.
研究 の 目的:
- 非腫瘍遺伝子依存性SOMDの治療における課題と論争について議論する.
- 現代免疫療法におけるLRTの役割を評価し,真のsOMD状態の存在を調査する.
主な方法:
- NRG- LU002試験を含む現在の文献と臨床試験データをレビューする.
- sOMDと広範囲に広がった病気を区別する際に転移の可能性とイメージングの限界に影響を与える生物学的要因の議論.
主要な成果:
- NRG- LU002試験では,オリゴメタスティックNSCLCの維持性全身療法にLRTを加えると,進行性のない生存期または全生存期において有意な改善は認められなかった.
- 現在のイメージング方法は,初期段階の広範囲に広がった転移性疾患と真のsOMDを確実に区別することができず,急進的な戦略のための患者の選択を複雑にします.
結論:
- 同期性オリゴメタスティックNSCLCが独立した生物学的存在であるかどうかについては議論されている.
- ctDNA,microRNA,radiomicsのようなバイオマーカーは,臨床試験における患者の選択を改善するためにさらなる検証を必要とし,トランスレーション研究の必要性を強調しています.
さらに関連する動画
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.2K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.6K
関連する概念動画
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:49Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K